Crenezumab, Roche’s Alzheimer’s disease (AD) candidate, has been shown to significantly reduce amyloid beta (A-beta) oligomers in cerebrospinal fluid (CSF) in patients in Phase II trials, supporting the proposed mechanism of action for the drug and moving it along the road to commercialization in a therapy area that has seen a lot fall by the wayside. However, the candidate has some significant ground to make up when compared with Biogen Inc.’s aducanumab.
Crenezumab is a fully humanized IgG4 monoclonal antibody that binds all forms of misfolded A-beta proteins, but especially to A-beta...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)